Retatrutide, a innovative dual-action GIP receptor agonist developed by Alluvi Biopharma, is sparking considerable buzz within the healthcare community as a leading advancement in weight management. Initial clinical data demonstrate a significant impact on body size, often outperforming current standard therapies. This remarkable mechanism of actio